Evolus Inc. named David Moatazedi president and chief executive. He comes from Allergan plc, where he was most recently senior vice president of U.S. medical aesthetics. He succeeds Murthy Simhambhatla, “who has decided to pursue other options,” according to a company press release.
Irvine-based Evolus is a lifestyle aesthetics company that focuses on private-pay medical opportunities. It restructured last year, narrowing its focus to develop a neurotoxin that produces similar cosmetic effects to Botox’.
Allergan’s aesthetic portfolio includes brands such as Botox and the derma filler Juvederm collection.
Evolus Chairman Vikram Malik said Moatazedi, “at forty years of age … [and] having led one of the largest and fastest growing franchises within Allergan,” will help Evolus “to compete in the fast-growing aesthetic market.”
Evolus neurotoxin DWP-450 is pending Food and Drug Administration approval.
Malik thanked Simhambhatla for his leadership and successfully taking the company public.
Shares in Evolus were 21% higher in late-afternoon trading to a $208 million market cap.
